Cardiologia Americas/United Health Group, São Paulo, Brazil.
Hospital Samaritano Paulista, São Paulo, Brazil.
Eur Heart J Acute Cardiovasc Care. 2023 Nov 16;12(11):755-764. doi: 10.1093/ehjacc/zuad082.
Chest pain is a major cause of medical evaluation at emergency department (ED) and demands observation to exclude the diagnosis of acute myocardial infarction (AMI). High-sensitivity cardiac troponin assays used as isolated measure and by 0- and 1-h algorithms are accepted as a rule-in/rule-out strategy, but there is a lack of validation in specific populations.
The IN-HOspital Program to systematizE Chest Pain Protocol (IN-HOPE study) is a multicentre study that prospectively included patients admitted to the ED due to suspected symptoms of AMI at 16 sites in Brazil. Medical decisions of all patients followed the standard approach of 0 h/3 h protocol, but, in addition, blood samples were also collected at 0 and 1 h and sent to a central laboratory (core lab) to measure high-sensitivity cardiac troponin T (hs-cTnT). To assess the theoretical performance of 0 h/1 h algorithm, troponin < 12 ng/L with a delta < 3 was considered rule-out while a value ≥ 52 or a delta ≥ 5 was considered a rule-in criterion (the remaining were considered as observation group). The main objective of the study was to assess, in a population managed by the 0 h/3 h protocol, the accuracy of 0 h/1 h algorithm overall and in groups with a higher probability of AMI. All patients were followed up for 30 days, and potential events were adjudicated. In addition to the prospective cohort, a retrospective analysis was performed assessing all patients with hs-cTnT measured during the year of 2021 but not included in the prospective cohort, regardless of the indication of the test. A total of 5.497 patients were included (583 in the prospective and 4.914 in the retrospective analysis). The prospective cohort had a mean age of 57.3 (± 14.8) and 45.6% of females with a mean HEART score of 4.0 ± 2.2. By the core lab analysis, 74.4% would be eligible for a rule-out approach (45.3% of them with a HEART score > 3) while 7.3% would fit the rule-in criteria. In this rule-out group, the negative predictive value for index AMI was 100% (99.1-100) overall and regardless of clinical scores. At 30 days, no death or AMI occurred in the rule-out group of both 0/1 and 0/3 h algorithms while 52.4% of the patients in the rule-in group (0 h/1 h) were considered as AMI by adjudication. In the observation group (grey zone) of 0 h/1 h algorithm, GRACE discriminated the risk of these patients better than HEART score. In the retrospective analysis, 1.091 patients had a troponin value of <5 ng/L and there were no cardiovascular deaths at 30 days in this group. Among all 4.914 patients, the 30-day risk of AMI or cardiovascular death increased according to the level of troponin: 0% in the group < 5 ng/L, 0.6% between 5 and 14 ng/L, 2.2% between 14 and 42 ng/L, 6.3% between 42 and 90 ng/L, and 7.7% in the level ≥ 90 ng/L.
In this large multicentre study, a 0 h/1 h algorithm had the potential to classify as rule-in or rule-out in almost 80% of the patients. The rule-out protocol had high negative predictive value regardless of clinical risk scores. Categories of levels of hs-cTn T also showed good accuracy in discriminating risk of the patients with a very favourable prognosis for cardiovascular death in the group with value < 5 ng/L.
CLINICALTRIALS.GOV: NCT04756362.
胸痛是急诊科(ED)进行医学评估的主要原因,需要进行观察以排除急性心肌梗死(AMI)的诊断。高敏心肌肌钙蛋白检测作为单一指标,以及 0 小时和 1 小时算法,被认为是一种排除或确诊的策略,但在特定人群中缺乏验证。
IN-HOspital Program to systematizE Chest Pain Protocol(IN-HOPE 研究)是一项多中心研究,前瞻性纳入了 16 个巴西站点因疑似 AMI 症状而入住 ED 的患者。所有患者的医疗决策均遵循 0 小时/3 小时方案的标准方法,但此外,还在 0 小时和 1 小时采集血样并送至中心实验室(核心实验室)测量高敏心肌肌钙蛋白 T(hs-cTnT)。为评估 0 小时/1 小时算法的理论性能,将<12ng/L 的 troponin 值且 delta<3 定义为排除标准,而将≥52ng/L 或 delta≥5 定义为纳入标准(其余为观察组)。该研究的主要目的是评估在 0 小时/3 小时方案管理的人群中,0 小时/1 小时算法的整体准确性,以及在 AMI 可能性较高的人群中的准确性。所有患者均随访 30 天,潜在事件由裁判裁定。除了前瞻性队列研究外,还进行了回顾性分析,评估了在 2021 年进行了 hs-cTnT 检测但未纳入前瞻性队列的所有患者,无论检测的适应证如何。共纳入 5497 例患者(前瞻性队列 583 例,回顾性分析 4914 例)。前瞻性队列患者的平均年龄为 57.3(±14.8)岁,45.6%为女性,平均 HEART 评分为 4.0±2.2。根据核心实验室分析,74.4%的患者适合排除方法(其中 45.3%的 HEART 评分>3),而 7.3%的患者符合纳入标准。在排除组中,索引 AMI 的阴性预测值为 100%(99.1-100),总体和无论临床评分如何。在 30 天时,0/1 小时和 0/3 小时算法的排除组中均未发生死亡或 AMI,而 0/1 小时算法纳入组的 52.4%(52.4%)的患者通过裁判裁定为 AMI。在 0 小时/1 小时算法的观察组(灰色区域)中,GRACE 比 HEART 评分更好地区分了这些患者的风险。在回顾性分析中,1091 例患者的 troponin 值<5ng/L,该组患者在 30 天内无心血管死亡。在所有 4914 例患者中,根据 troponin 水平,AMI 或心血管死亡的 30 天风险增加:<5ng/L 组为 0%,5-14ng/L 组为 0.6%,14-42ng/L 组为 2.2%,42-90ng/L 组为 6.3%,≥90ng/L 组为 7.7%。
在这项大型多中心研究中,0 小时/1 小时算法几乎可以对近 80%的患者进行纳入或排除。排除方案具有较高的阴性预测值,无论临床风险评分如何。hs-cTnT 水平类别也显示出良好的准确性,可区分预后良好的心血管死亡患者的风险。
NCT04756362。